Future considerations for the mRNA-lipid nanoparticle vaccine platform

Vaccines based on mRNA-containing lipid nanoparticles (LNPs) pioneered by Katalin Karikó and Drew Weissman at the University of Pennsylvania are a promising new vaccine platform used by two of the leading vaccines against coronavirus disease in 2019 (COVID-19). However, there are many questions rega...

Descripción completa

Detalles Bibliográficos
Autores principales: Igyártó, Botond Z, Jacobsen, Sonya, Ndeupen, Sonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065267/
https://www.ncbi.nlm.nih.gov/pubmed/33906124
http://dx.doi.org/10.1016/j.coviro.2021.03.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065267/
https://www.ncbi.nlm.nih.gov/pubmed/33906124
http://dx.doi.org/10.1016/j.coviro.2021.03.008

Ejemplares similares